BME100 f2013:W900 Group13 L2

From OpenWetWare

Jump to: navigation, search
BME 100 Fall 2013 Home
People
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Photos
Wiki Editing Help
Image:BME494_Asu_logo.png


Contents

OUR TEAM

Name: Allison MarleyRole(s)
Name: Allison Marley
Role(s)
Name: Tyler AngellRole(s)
Name: Tyler Angell
Role(s)
Name: Cory RieckenRole(s)
Name: Cory Riecken
Role(s)
Name: Andrew LucRole(s)
Name: Andrew Luc
Role(s)
Name: Reem GeraisRole(s)
Name: Reem Gerais
Role(s)
Name: studentRole(s)
Name: student
Role(s)

LAB 2 WRITE-UP

Descriptive Statistics

Human Study Data

Image:Human Study Data.jpg


Rat Study Data

Image:Rat Study data.jpg





Results

Experiment 1[Human Study]

Image:inflammotin vs lps dose.jpg


Experiment 2[Rat Study]

Image:Effect of LPS dosage on Inflammotin levels in Rats.jpg





Analysis

Experiment 1 [Human Study]
Image:MoreStudies.jpg

Image:Posthoctests.jpg

Image:Human_Study.jpg

Results from the experiment yielded a P-value of 1.40x10^-6 which is significantly lower than 0.05. From this, we took a post-hoc test to validate the significance between the individual dosages. Our data showed that there are significant differences between each of the dosages.

Experiment 2 [Rat Study]

T-Test Image:Example.jpg

Image:T-test chart.jpg Using statistics, we computed a P-value of approxiamtly .867. Therefore since our p-value is greater than .05, we have concluded that our p-value shows no significant difference between the two dosages in rats. (Using inferential statistics, please determine statistically significant differences in the data.)





Summary/Discussion

Experiment 1 (Human Study): The analysis shows that there is a clear and present correlation between the dosage of lipopolysaccharide and inflammotin production in human subjects however there is a high variance among test subjects who took higher doses and so our data, analysis, and conclusion may be unreliable.

Experiment 2 (Rat Study): Our analysis shows no correlation between lipopolysaccharide dosage and inflammotin production in rats, but since there were so few test subjects, the results may not be representative of rats as a population and so more tests would need to be done with more subjects to find definite results.

From the results we can see that there is a large increase in inflammotin production in humans as the dosage of LPS increases, however we can see that the deviation between subjects increases in relation to the dosage. This large variance between subjects receiving higher doses means that more work needs to be done in order to have clear, reliable results. On the other hand there is little increase in inflammotin production in rats when the dosage of LPS increases, but like the humans there is an increase in the standard error as the dosage increases. This high deviation when there is a high dosage means that as the dosage increases, our data and consequently our results are less accurate. With that in mind, our analysis of the results in humans showed a p-value of 1.40E-16, which means that there is a definite difference in inflammotin production in relation to dosage of LPS, which means that increasing the dosage of LPS will have a significant impact on inflammotin production. In our analysis of the results in rats we found that the p-value= 0.8674035, which means there is little difference in inflammotin production between the different dosages of LPS, so increasing the dose of LPS will not cause a meaningful change in inflammotin production in rats.







Personal tools